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Comparison of tobramycin 80 mg (IV-preparation) and 300 mg 
soluSon inhaled twice daily for chronic/~ aeruginosa infection 
W.H. Nikula iz ik  1, D. Vietzke 2, F. Ratjen 2
iAuguste-Vlktoria-Hospital, Bad Lippspringe, 2Dept of Paediatrics, Univemity 
Hospital Essen, Germany 
Aims:  In an upen study with a crussuver design we have cumpared the effect uf 
cuntinuuus twice daily administration uf 80 mg tubramycin tu that uf  intermittent 
administratiun uf 300 mg tubramycin in CF patients cbrunically infected w i th /~ 
aemginosa. 
Methods:  A l l  subjects received culistin (1 Mi l l  U b.i.d.) fur 3 munths befure b ing 
r andumly allucated tu either 80 mg ur 300 mg uf t ubr amycin b.i.d. After 3 munths, 
patients were switched tu the alternative treatment regimen. Lung functiun and 
sputum bacteriulugy were assessed befure and after each treatment cycle. Patient 
preference uf the different reatment regimens was alsu documented. 
Results: 32 patients (mean age + SD: 18.5 + 8.6 years) cumpleted the trial. There 
was nu difference in age, sex ur lung functiun at baseline between the gruups. 18 
patients were initial ly treated with luw duse and 14 patients with high duse 
tubramycin. Cumpared tu the treatment period with culistin, mean (SD) FEV1 
decreased by 2.1 (14) % ha the luw duse tubramycin gruup and increased by 1.4 
(12.5) % in the high duse gruup. Similar changes were ubserved fur FVC ( 2.3 vs. 
+ 2.1%). Variability in respunses was large and these differences failed tu reach 
statistical significance. Of  the 32 patients cumpleting buth treatment arms 19 
preferred the higher duse uf tubr amycin, 7 the luwer duse uf t ubr amycin, 3 culistin, 
whereas 3 had nu  preference. 
Conduslons:  A trend tuwards better lung functiun was ubserved fur the 300 mg 
tubramycin gruup that tai led tu reach statistical significance. Must patients 
preferred the higher duse uf tubramycin fur mulated fur inhalatiun tu the luwer duse 
prepar atiun. 
Supported by Chiro~ Germany 
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Effect of TOBI continuous therapy on pulmonary funcSon in CF 
pa~ents 
G.L. Gr zincich l, A. Mianc2, G. Pisi l, C. Spaggiari l, M.C. Tripodi l
~Cystic Fibrosis Center University of Parma Italy, 2Cystic Fibrosis Center of 
Cesena- Italy 
Introduct ion:  The clinical course of CF lung disease correlates with the acquisition 
of/~ aeruginosa (Pa) chrunic infectiun. 
TOBI (tobramycin ebuliser solution) is l icensed for the long term management of 
chronic respiratory pseudomonal infection. 
A im:  To asses the effects of TOBI on pulmonary function in CF patients chronically 
infected with Pa. 
Subjects and  methods:  We studied seventy clinically stable patients (35 M), 
median age 22.5 yrs (range 7 41 yrs), 28 humuzyguus fur DF508, mean age Pa 
colonization 12,9 yrs (range: 2 25 yrs). Replacing a different inhaled antibiotic, 70 
pts perfurmed TOBI (300 mg bid, every other month) fur 1 year and 51 fur 2 yrs. 
Calculating the annual changes uf FEV 1 values (DFEVI) , we cumpared the mean 
values of the 3 yrs preceding TOBI therapy to the ones during treatment (paired t test). 
Based on annual DFEVI, we  divided our patients into 3 subgroups: worsened (W) 
(change < 2% ), unchanged (U) (between 2 and +2%) and impruved subjects (1) 
(> + 2 %). We compared the prevalence of patients in each subgroup with mad 
without TOBI treatment (chi square analysis). P value less than 0.05 was cunsidered 
as significant. 
Results: The mean (+ SD) annual DFEV 1 are shown in the table beluw. 
NO TOBI TOBI 
3 2th yrs 2 lzt yrs 0 lzt yrs 1 2th yrs 
2.5+8.4 3.3+8.2 *+0.6+8.6 0.9+8.8 
* p <0.02 
During TOBI therapy, the prevalence u fW pts is significantly luwer than the une in 
the years withuut TOBI (42% vs. 56%, p<0.05). 
Condtts ion:  Our results, according tu literature, suggest hat TOBI therapy can 
reduce pulmonary function decline in CF patients with chronic Pa infection; this 
could be related, beside its antimicr obial activity, to an action on CF IR  function. 
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Fur patients with cystic fibrusis, therapy uf cbrunic pseudumunas aeruginusa 
infectiun is essential tu impr uve their quality uf l ife and the cuurse uf their disease. 
Thus a t ime mad cost efficient hahalatiun uf Tubramycin, in an acceptable drug 
cuncentratiun, is cmcial, fikarrently, the must used Tubramycin fur iohalatiun is 
TON ® . 
The aim uf  the study was tu determine, that inhalatiun uf GERNEBCIN ® 
(hffectupharm), cumbined with a luwer f i l l ing duse, wuuld result in a cumparable 
lung depusitiun uf drug substance when supplied with the AKITA device, which has 
a much higher depusitiun efficiency cumpared tu cunventiunal nebulizers. 
In this randumized cruss uver study, 6 healthy subjects iohaled 300 mg TOBI ®, 
f i l l ing vu lume 5 ml, using a Par i  Turbu Buy N®/LC Plus mad 160 mg 
GERNEB CIN ®, f i l l ing vulume 4 ml, using AKITA System/Pari LC Star. 
Inhalatiun uf TOBI ® (5 ml/3CO rag) results in 34 + 7 mg depusitiun uf Tubr amycin 
in the lungs, whi le  hahalatiun uf GERNEB CIN ® (4 ml/160 rag) results in 50 + 5 mg 
depusitiun in the lungs. Time tu depusit 1 mg in the lungs was nut significantly 
different (TOBI®: 0.33 rain/rag, GERNEBCIN ® 0.40 mha/mg). 
Cumpared tu the h~halatiun uf TOBI ® the drug amuunt depusited ha the lungs was 
significantly higher fur GERNEBCIN ® and costs fur depusiting une gram were 
much luwer (TOBI 1 .~/mg depusited, GERNEBCIN 0 .36~/mg depusited). By 
pre setting the dusage via  patient individualized smart card the equivalence duse 
tu Tubi can be set. The luwer drug cuncentratiun i  GERNEB CIN ® might alsu lead 
tu a higher acceptance in CF patients, because uf the lesser urupharyngeal 
ir~itatiuns. 
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2MU (160MG.) Colistimethate Twice Daily is a safe Nebulized dose for 
Adults and Children with Cystic Fibrosis 
M.H. Guldman, S.J. Stramik, K. Girdwuod 
Forest Laboratories U.K. Ltd, Be~Iey, Kent, DA5 INX, United Kingclom 
The safety uf 2MU culistimethate n bulized twice daily in patients aged 8 years mad 
buve was investigated in a phase I study, with emphasis un tulerabil ity including 
markers uf renal tubular damage (urinary N acetyl [~ glucusaminidase (NAG) and 
urinary o: 1 micruglubulin (alto)). 
12 patients aged 8 years and abuve with cystic fibrusis and lung infectiun with 
Raeruginusa, were given 2MU culistimethate nebulized twice daily fur 28 days. 
Clinical safety uf inhaled culistimethate was evaluated using spuntaneuusly 
repur ted and sulicited events frum a checklist and diary cards. Pulmunary functiun 
was measured pre and pust ther apy.10 patient's data are presented. 
Age ranged frum 10.5 tu 54.6 years (mean 25.3y). 4 patients had received 
culistimethate 1MU twice daily mad 6 patients 2 MU twice daily priur tu the study. 
The cummunest repurted events were chest tightness, wheezing and cuugh, but 
were nut reflected by ubjective change in PFT. The mean pretreat ment %predicted 
FEV1 was 69.0% and was 70.8% at 28 days. Pretreatment duse did nut affect 
uutcume. 
The mean calculated creatinine clearance was 97.3mlhnin pre4reatment and 94.2 
pust treatment. There was marked inter and intra patient differences in markers uf 
renal  tubular damage. Mean urinary creat inine changed frum 11.7(S.D. 
5.0)mmul/ l  tu 9.3(S.D . 5.8)mmul/l .  Mean urinary NAG/creatinine ratiu was 
almost tmchanged frum 23.4(S.D. = 32.3) tu 22.1(S.D. = 9.8) U/mmul  creatinine. 
Mean alm/creat inine ratiu changed frum 0.53(S.D. 0.27) tu 1.14(S.D. 0.94) 
mg/mmul creatinine. 
Nu  patient discuntinued nebulized culistimethate therapy due tu unt uward event ur 
abnurmal laburatury findings. 
These l imited data suggest that nebulizing 2MU culistimethate twice daily is a safe 
therapy fur patients with cystic fibrusis. 
